Lilly(Eli) & Co (LLY) concluded trading on Wednesday at a closing price of $829.84, with 3.85 million shares of worth about $3.2 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.23% during that period and on December 04, 2024 the price saw a gain of about 2.03%. Currently the company’s common shares owned by public are about 950.22M shares, out of which, 850.67M shares are available for trading.
Stock saw a price change of 5.13% in past 5 days and over the past one month there was a price change of 2.94%. Year-to-date (YTD), LLY shares are showing a performance of 42.36% which increased to 41.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $561.65 but also hit the highest price of $972.53 during that period. The average intraday trading volume for Lilly(Eli) & Co shares is 3.59 million. The stock is currently trading 5.85% above its 20-day simple moving average (SMA20), while that difference is down -2.15% for SMA50 and it goes to -0.89% lower than SMA200.
Lilly(Eli) & Co (NYSE: LLY) currently have 950.22M outstanding shares and institutions hold larger chunk of about 72.76% of that.
The stock has a current market capitalization of $787.78B and its 3Y-monthly beta is at 0.40. PE ratio of stock for trailing 12 months is 90.78, while it has posted earnings per share of $9.14 in the same period. Its PEG reads 2.75 and has Quick Ratio of 0.97 while making debt-to-equity ratio of 2.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LLY, volatility over the week remained 1.93% while standing at 2.94% over the month.
Stock’s fiscal year EPS is expected to rise by 110.21% while it is estimated to increase by 68.77% in next year. EPS is likely to grow at an annualized rate of 33.00% for next 5-years, compared to annual growth of 13.74% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on November 15, 2024 offering an Outperform rating for the stock and assigned a target price of $1000 to it. Coverage by Bernstein stated Lilly(Eli) & Co (LLY) stock as an Outperform in their note to investors on October 17, 2024, suggesting a price target of $1100 for the stock. On September 13, 2024, Citigroup Resumed their recommendations, while on August 12, 2024, Deutsche Bank Upgrade their ratings for the stock with a price target of $1025. Stock get a Hold rating from DZ Bank on February 21, 2024.
